Why insider trading matters?

Numerous studies have examined whether there is evidence that U.S. insiders systematically trade on private information despite the legal deterrence. The consensus appears to be that insider purchases (but not sales) tend to be followed by positive abnormal stock price performance, particularly for small growth stocks.

- Prof. B. Espen Eckbo, Dartmouth College
NEVRO CORP (NVRO)
Sector: Healthcare; Industry: Medical Devices

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. It also offers Senza II system and Senza Omnia system products for chronic pain. The company's solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-03-10 Pellegrini Niamh Louise Chief Commercial Officer Sell 750 $148.08 $111,060 Yes
2021-03-01 Vale Brad Director Sell 5,303 $167.84 $890,039 No
2021-02-10 Pellegrini Niamh Louise Chief Commercial Officer Sell 750 $182.55 $136,912 Yes
2021-01-11 Pellegrini Niamh Louise Chief Commercial Officer Sell 750 $169.80 $127,350 Yes
2020-12-10 Pellegrini Niamh Louise Chief Commercial Officer Sell 750 $161.21 $120,910 Yes
2020-11-10 Pellegrini Niamh Louise Chief Commercial Officer Sell 750 $170.75 $128,062 Yes
2020-10-22 Pellegrini Niamh Louise Chief Commercial Officer Sell 1,817 $165.00 $299,805 No
2020-10-19 Pellegrini Niamh Louise Chief Commercial Officer Sell 1,000 $155.00 $155,000 No
2020-10-13 Pellegrini Niamh Louise Chief Commercial Officer Sell 1,750 $150.63 $263,602 Yes
2020-10-12 DEMANE MICHAEL F Director Sell 21,432 $150.35 $3,222,287 No
2020-09-16 DEMANE MICHAEL F Director Sell 18,028 $146.42 $2,639,587 No
2020-09-10 Pellegrini Niamh Louise Chief Commercial Officer Sell 750 $139.14 $104,355 Yes
2020-09-02 DEMANE MICHAEL F Director Sell 3,400 $145.25 $493,864 No
2020-08-27 DEMANE MICHAEL F Director Sell 18,900 $141.01 $2,665,004 No
2020-08-13 DEMANE MICHAEL F Director Sell 300 $140.05 $42,016 No
2020-08-10 DEMANE MICHAEL F Director Sell 87,940 $135.68 $11,931,494 No
2020-08-10 Pellegrini Niamh Louise Chief Commercial Officer Sell 750 $140.11 $105,082 Yes
2020-05-21 McCormick Shawn Director Sell 1,020 $126.50 $129,030 No
2020-02-28 Schmitz Patrick Vice President, Operations Sell 42,884 $128.78 $5,522,574 Yes
2020-01-08 Galligan Andrew H Chief Financial Officer Sell 17,718 $120.11 $2,128,086 Yes
2020-01-06 Galligan Andrew H Chief Financial Officer Sell 2,782 $120.00 $333,840 Yes
2019-11-25 Galligan Andrew H Chief Financial Officer Sell 12,000 $110.39 $1,324,714 Yes
2019-11-25 Alleavitch Doug VP, Quality Sell 1,000 $110.00 $110,000 No
2019-11-11 McCormick Shawn Director Sell 800 $104.35 $83,480 No
2019-11-11 DEMANE MICHAEL F Director Sell 50,000 $103.70 $5,185,163 No
2019-11-11 Galligan Andrew H Chief Financial Officer Sell 18,522 $103.70 $1,920,731 Yes
2019-11-07 Alleavitch Doug VP, Quality Sell 1,000 $100.00 $100,000 No
2019-06-07 WEATHERMAN ELIZABETH H Director Buy 8,183 $61.22 $500,981 No
2019-06-05 OBOYLE KEVIN C Director Buy 1,675 $60.00 $100,500 No
2018-05-14 Galligan Andrew H Chief Financial Officer Sell 7,000 $76.14 $532,959 Yes

Insider Smart

Altimmune, Inc. (ALT) - Venrock Healthcare Capital Partners III, L.P., 10%-owner of ALT bought 1.3M shares in late May then added another 1.5M shares in June with an averaged ~$8 per share. 10 days after the accumulation, ALT price jumped to $10.

Insider Smart

ROYAL CARIBBEAN CRUISES (RCL) - Thompson Donald, Director of RCL feels safe and made a move. The only insiders bought RCL post crash.